obesity drug news today glp-1 oct 27 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1 Pharmacy Pricing Update (Dec

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

The Semaglutide Weight Loss Program is a clinician-guided telehealth program built around compounded semaglutide, a GLP-1 medication that supports appetite control, quiets food noise, and makes a calorie deficit easier to sustain

PROMOTE HEALTHY FAT LOSS

A dual GIP/GLP-1 agonist studied in metabolic research

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction

Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]